EN
Tissue plasminogen activator tPA is used for treatment of ischemic stroke patient. This thrombolytic agent resurrect blood supply to brain tissue, that is sensitive to oxygen and glucose deprivation. Administration of tPA is the only approved treatment and might be conducted up to 3 or 4.5 hours after ischemic stroke symptom onset. The benefits of it are time dependent and there is need for an improvement the timeliness of reperfusion. Some side effects of tPA is caused likely by its matrix metalloproteinase-9 (MMP-9) activation. Source and localization of MMP9 is still uncertain. This is investigated with high resolution in situ zymography. We use mouse model of in situ thromboembolic stroke and reperfusion as a clinically relevant. In this experimental set we identify oligodendrocytes and neurons but not astrocytes and microglia as a cellular source of gelatynolytic activity. Oligodendrocytes activity is most prominent. This is in opposition to literature. Activity of leukocytes is high however number of them suggest that their contribution to overall activity is negligible.